Healthcare -
Biotechnology - NASDAQ - US
$ 4.65
-9.71 %
$ 414 M
Market Cap
-1.05
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Amylyx Pharmaceuticals, Inc.
| Revenue | 87.4 M |
| Cost Of Revenue | 42.2 M |
| Gross Profit | 45.2 M |
| Operating Expenses | 360 M |
| Operating Income | -315 M |
| Other Expenses | -13 M |
| Net Income | -302 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Revenue | 87.4 | 380.8 | 22.2 | 0.3 | 0.7 | 1.4 |
| GROSS PROFIT | ||||||
| Cost Of Revenue | 42.2 | 25.4 | 3.0 | 52 K | 24.6 | 11.9 |
| Gross Profit | 45.2 | 355.3 | 19.2 | 0.2 | (23.9) | (10.5) |
| OPERATING INCOME | ||||||
| Operating Expenses | 359.9 | 316.5 | 220.6 | 82.7 | 39.0 | 13.6 |
| Selling, General and Administrative Expenses | 114.3 | 188.4 | 127.1 | 38.9 | 15.1 | 3.1 |
| Research and Development Expenses | 104.1 | 128.2 | 93.5 | 44.0 | 24.6 | 11.9 |
| Operating Income | (314.7) | 38.8 | (201.3) | (82.7) | (39.0) | (13.6) |
| PRE-TAX INCOME | ||||||
| Interest Income Expense | 0 | 0 | 4.3 | 0 | 2.3 | 1.3 |
| Total Other Income | 12.6 | 15.5 | 3.7 | (5.2) | (3.3) | (0.2) |
| Pre-Tax Income | (302.1) | 54.3 | (197.6) | (87.9) | (42.3) | (13.7) |
| NET INCOME | ||||||
| Tax Provision | (0.4) | 5.0 | 0.8 | 52 K | 2.6 | 1.1 |
| Net Income | (301.7) | 49.3 | (198.4) | (87.9) | (44.8) | (14.8) |
| EPS | 4.43 | 0.73 | 2.98 | 1.52 | 0.79 | 0.26 |